All In Biotech

Drug Trial Radar · NCT04006457

Long-Term PF-06651600 for the Treatment of Alopecia Areata

A PHASE 3 OPEN-LABEL, MULTI-CENTER, LONG-TERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF-06651600 IN ADULT AND ADOLESCENT PARTICIPANTS WITH ALOPECIA AREATA

Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,057

Actual

Start

Jul 18, 2019

Primary completion

Jun 25, 2024

Study completion Feb 26, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jul 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug. A sub-study of approximately 60 adult patients who are participating in the B7981032 study will be conducted at select sites in the US, Australia and Canada. The sub-study will evaluate the immune response to tetanus and meningococcal vaccines in patients who have received a minimum of 6 months of 50 mg PF-06651600.

Conditions

  • Alopecia Areata

Interventions

  • PF-06651600Drug

    50 mg oral tablets/capsules

  • Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccineBiological

    Single intramuscular injection administered to patients participating in the vaccine sub-study

  • Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccineBiological

    Single intramuscular injection administered to patients participating in the vaccine sub-study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up VisitTime frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
  2. Main Study: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation Until Follow-up VisitTime frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
  3. Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up VisitTime frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
  4. Main Study: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values Until Follow-up VisitTime frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
  5. Vaccine Sub-study: Percentage of Participants With Tetanus Booster ResponseTime frame: Month 1

Locations

144 sites in 17 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham Hosptial Outreach Lab

    Birmingham, Alabama

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • The University of Alabama at Birmingham, Department of Dermatology

    Birmingham, Alabama

  • Mosaic Dermatology

    Beverly Hills, California

  • Univ of California, Irvine, Dermatology Clinical Research Center

    Irvine, California

  • Dermatology Specialists Inc.

    Murrieta, California

  • University of California, San Francisco

    San Francisco, California

  • Kaiser Permanente Clinical Trials Unit

    San Francisco, California

  • Southern California Dermatology, Inc.

    Santa Ana, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • University of Colorado Hospital Clinical and Translational Research Center

    Aurora, Colorado

  • University of Colorado Hospital Outpatient Pavilion

    Aurora, Colorado

  • Yale School of Medicine, Yale Center for Clinical Investigations

    New Haven, Connecticut

  • Medstar Georgetown University Hospital - Department of Otolaryngology

    Washington D.C., District of Columbia

  • Medstar Georgetown University Hospital-Dept of Otolaryngology

    Washington D.C., District of Columbia

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • Medstar Georgetown University Hospital - Department of Pediatrics

    Washington D.C., District of Columbia

  • Siperstein Dermatology Group

    Boynton Beach, Florida

  • Park Avenue Dermatology

    Orange Park, Florida

  • ForCare Clinical Research

    Tampa, Florida

  • Velocity Clinical Research - Boise

    Meridian, Idaho

  • Northwestern Medical Group

    Chicago, Illinois

  • Northwestern Medicine Diagnostic Testing Center

    Chicago, Illinois

  • Northwestern Medicine

    Chicago, Illinois

  • Northwestern Memorial Hospital Investigational Drug Service Pharmacy

    Chicago, Illinois

  • Summit Dermatology and Aesthetic Surgery (in c/o TrialSpark, Inc)

    Oakbrook Terrace, Illinois

  • NorthShore University HealthSystem Dermatology Clinical Trials Unit

    Skokie, Illinois

  • Southern Illinois University School of Medicine

    Springfield, Illinois

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Medstar Georgetown University Hospital - Department of Dermatology

    Chevy Chase, Maryland

  • Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS)

    Boston, Massachusetts

  • University of Minnesota Clinical Research Unit (CRU)

    Minneapolis, Minnesota

  • University of Minnesota Lillehei Clinical Research Unit (LCRU)

    Minneapolis, Minnesota

  • University of Minnesota Medical Center, Investigational Drug Services Attn: Darlette Luke

    Minneapolis, Minnesota

  • Skin Specialists, PC (Schlessinger MD)

    Omaha, Nebraska

  • Schweiger Dermatology, P.C.

    Verona, New Jersey

  • NYU School of Medicine, The Ronald O. Perelman Department of Dermatology

    New York, New York

  • Pura Dermatology (in c/o TrialSpark, Inc)

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

Showing 40 of 144 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.